CSIMarket
 
Intellia Therapeutics Inc   (NTLA)
Other Ticker:  
 

Intellia Therapeutics Inc

Business Description


Intellia Therapeutics Inc. is a biotechnology company focused on developing revolutionary genome editing technologies to treat genetic diseases. Founded in 2014, the company is headquartered in Cambridge, Massachusetts, United States.

Intellia Therapeutics is widely known for its expertise in CRISPR/Cas9 gene editing technology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring system found in bacterial immune systems that allows precise editing of genes. Intellia Therapeutics has harnessed this technology to develop therapeutic strategies to modify the DNA of cells with the aim of correcting or eliminating the underlying genetic causes of diseases.

The company*s research primarily revolves around developing CRISPR/Cas9 as a powerful tool to selectively modify target genes in a precise and specific manner. Intellia Therapeutics aims to leverage this technology to develop one-time treatments for genetic diseases that have been historically challenging to treat.

Intellia Therapeutics? therapeutic pipeline is focused on three areas: in vivo editing, ex vivo editing, and engineered cell therapies. In vivo editing refers to editing genes within the body, while ex vivo editing involves modifying genes in cells outside the body before reintroduction to the patient. Engineered cell therapies involve genetically modifying cells to enhance their therapeutic potential.

The company has collaborated with various partners, including Regeneron Pharmaceuticals, Novartis, and Ospedale San Raffaele, to advance its research and development efforts. Through these partnerships, Intellia Therapeutics has been able to combine its gene editing technology with the expertise of its collaborators to accelerate the development of novel therapies.

In terms of its clinical pipeline, Intellia Therapeutics is actively developing multiple programs for the treatment of genetic diseases. The company*s lead program is focused on the development of a potential treatment for transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the buildup of abnormal protein deposits in various tissues and organs.

Apart from ATTR, Intellia Therapeutics is also exploring the application of its technology in treating other diseases such as hereditary angioedema (HAE), acute myeloid leukemia (AML), and sickle cell disease, among others.

In addition to its therapeutic programs, Intellia Therapeutics is committed to advancing the field of gene editing by actively investing in research and development activities. The company aims to improve the efficiency and specificity of its gene editing technologies and expand their applicability to a wider range of diseases.

As a company at the forefront of gene editing technology, Intellia Therapeutics places a strong emphasis on ensuring the safety and ethical use of its technologies. The company adheres to strict regulatory guidelines and ethical standards to ensure that its therapies are developed and deployed in a responsible and beneficial manner.

Overall, Intellia Therapeutics is a leading biotechnology company that leverages CRISPR/Cas9 technology to develop innovative therapies for genetic diseases. With its extensive research and development efforts, strategic partnerships, and commitment to ethical practices, the company is poised to pave the way for groundbreaking advancements in the field of gene editing.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com